ARQT vs SNY: Which Is the Better Buy in 2026?
Last updated November 2026
Short answer
SNY is the larger of the two ($111.81B market cap): the incumbent the market prices for continued execution (8.58x forward earnings, beta 0.26). ARQT is the smaller challenger ($3.37B), actually pricier on forward earnings (24.37x): more room to run, but more to prove. If you believe in growth, ARQT fits: analysts expect its revenue to rise 30% next year, against 7% for SNY. If you believe in paying less for profit, SNY fits: it trades at 8.58x forward earnings, against 24.37x for ARQT.
ARQT vs SNY: the tie-breaker metrics
Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.
| Metric | ARQT | SNY | What it tells you |
|---|---|---|---|
| Market cap | $3.37B | $111.81B | Size. The larger name is the incumbent; the smaller has more room to grow and more to prove. |
| Forward P/E | 24.37 | 8.58 | Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up. |
| Trailing P/E | 121.23 | 23.17 | Valuation on the last 12 months. A big drop from trailing to forward means the market expects earnings to jump, so more growth is already in the price. |
| Beta | 1.63 | 0.26 | Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through. |
| Price vs 52-week range | 48% of range | 65% of range | Where today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why. |
| Price / book | 13.78 | 1.36 | How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price. |
Reading it: SNY is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.
Before you buy: how ARQT and SNY affect your concentration
The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. ARQT and SNY share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.
This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined ARQT and SNY exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.
What does Arcutis Biotherapeutics (ARQT) do?
Arcutis Biotherapeutics is a commercial-stage biopharmaceutical company focused on medical dermatology. Its business is built around ZORYVE, a topical formulation of roflumilast that inhibits phosphodiesterase type 4 (PDE4), an anti-inflammatory target long used in dermatology. ZORYVE is sold as a cream 0.3% for plaque psoriasis, a foam 0.3% for seborrheic dermatitis, and cream formulations (0.15% and 0.05%) for atopic dermatitis spanning adults down to young children. The pitch to dermatologists is a steroid-free, once-daily topical with a clean tolerability profile that can be used on sensitive and intertriginous skin, and the company markets it as the leading branded topical across those three inflammatory skin conditions combined.
What does Sanofi (SNY) do?
Sanofi S.A. is one of the world's largest pharmaceutical companies, based in France and organized around biopharma (specialty care, general medicines) and vaccines. Its single most important product is Dupixent, an immunology drug co-developed with Regeneron that treats conditions like eczema, asthma, and COPD; Dupixent sales moved above the roughly four-billion-euro-per-quarter mark in Q1 2026 and reached about 5.7 billion euros in Q3 2026, up nearly 35% year over year, making it the engine of the company's revenue growth. Sanofi also runs a major vaccines business (including the RSV antibody Beyfortus and the newly acquired hepatitis-B vaccine Heplisav-B) and spun off its consumer-health arm, Opella (Allegra, Icy Hot, Dulcolax), in 2025 to focus purely on innovative medicines and vaccines.
ARQT vs SNY: how do they differ?
Both fit overlapping themes, but they are not interchangeable. Here is what each one depends on.
- ARQT drivers: Multi-indication ZORYVE expansion; Revenue growth reaching profitability.
- SNY drivers: Dupixent as the growth engine; Pipeline and new launches.
Which fits which kind of investor
A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: The dominant risk is single-product concentration: nearly all revenue depends on ZORYVE, so any slowdown in prescriptions, an unfavorable payer or pricing shift, a safety signal, or eventual generic and patent challenges would hit the whole company. For SNY, the clearest risk is concentration in Dupixent: with one product carrying so much of the growth, its eventual loss of patent exclusivity later this decade is the central overhang, and the pipeline may or may not fully replace it.
ARQT or SNY: which should you pick?
If the story you believe is ARQT's (Multi-indication ZORYVE expansion), ARQT is the more direct way to own it; if it is SNY's (Dupixent as the growth engine), SNY is. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the ARQT and SNY guides.
ARQT vs SNY: the full fundamentals
ARQT. As of November 2026, Arcutis trades at about 6.6 times TTM sales and roughly 121 times trailing earnings, a multiple that only makes sense against forward estimates (about 24 times), since earnings are just turning positive. Analysts expect 2026 EPS of about $0.33, down from $0.43 before the Q3 miss, rising to about $1.09 in 2027 on revenue near $703 million, so the valuation leans on ZORYVE's revenue trajectory and on spending growing more slowly than sales. The eight analysts Yahoo Finance tracks have a mean target near $40.
SNY. Figures are approximate and tied to data as of November 20, 2026. The gap between a ~23x trailing P/E and a ~8.6x forward P/E reflects one-off charges in reported profit versus analyst estimates based on business earnings, and the yield has eased to ~5.3% as the ADR recovered about 12% in the month after third-quarter results, when Sanofi upgraded its full-year 2026 guidance. Sanofi reports in euros, so the dollar value of SNY and its dividend also depends on the euro-to-dollar exchange rate; fourth-quarter results are scheduled for January 28, 2027.
Headline figures (approximate, November 2026): ARQT shows revenue (ttm) ~$509 million, revenue growth (q3 2026, year over year) ~45%, q3 2026 net income ~$8.8 million (EPS $0.06 vs $0.17 est.), 2026 revenue guidance $535 to $545 million (raised); SNY shows company type Large-cap, diversified global pharmaceutical company (French, US-listed as an ADR on Nasdaq), market cap ~$112 billion (ADR ~$46.58), revenue (ttm) ~51.0 billion euros; Q3 2026 ~14.4 billion, up ~15.7% year over year, q3 2026 eps (actual vs est.) 1.98 vs ~1.51 (adjusted, Yahoo Finance basis).
The bottom line: ARQT vs SNY
ARQT and SNY are related but distinct: same themes, different businesses and risks. Neither wins in the abstract, and whichever you pick is worth sizing so one theme does not take over your portfolio. Walnut can show your combined ARQT and SNY exposure against your real portfolio. It is not an investment adviser.
Wondering how ARQT or SNY fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Your questions about Arcutis Biotherapeutics
Ask Walnut's AI anything about ARQT and see how it fits what you own.
FAQ
What is the difference between ARQT and SNY?
+
Arcutis Biotherapeutics is a commercial-stage biopharmaceutical company focused on medical dermatology. Sanofi S.A. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.
Is ARQT or SNY the better stock?
+
Neither is universally better. SNY is the larger incumbent; ARQT is the smaller challenger and looks pricier on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.
Which is cheaper, ARQT or SNY?
+
On forward P/E (as of November 2026), ARQT trades at 24.37x and SNY at 8.58x, so SNY is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.
Should you own both ARQT and SNY?
+
Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.
What are the risks of ARQT vs SNY?
+
ARQT: The dominant risk is single-product concentration: nearly all revenue depends on ZORYVE, so any slowdown in prescriptions, an unfavorable payer or pricing shift, a safety signal, or eventual generic and patent challenges would hit the whole company. Profitability is early and inconsistent, with Q1 2026 returning to a loss of about $11 million on seasonality and reinvestment before Q2 recovered, and Q3 net income of about $8.8 million fell short of estimates as spending grew faster than revenue, and the business carries a large accumulated deficit built up over its pre-commercial years. Competition is real, including Incyte's Opzelura (a JAK-inhibitor cream), Dermavant's Vtama (tapinarof), generic topical steroids, and systemic biologics like Dupixent in atopic dermatitis. Gross-to-net adjustments, rebates, and inventory timing can make quarterly revenue lumpy, and continued sales-force and marketing spend can keep operating results volatile even as demand grows. Valuation now assumes that growth continues: the stock trades near 6.6 times sales and about 24 times forward earnings, and an insider sale of about $1.4 million was disclosed in November 2026, and the infant label still depends on an FDA decision expected by February 23, 2027. SNY: The clearest risk is concentration in Dupixent: with one product carrying so much of the growth, its eventual loss of patent exclusivity later this decade is the central overhang, and the pipeline may or may not fully replace it. Drug development is inherently uncertain, as the December 2025 US complete response letter for tolebrutinib in non-relapsing secondary progressive MS showed, even as the EU approved it. Because SNY is an ADR of a euro-reporting company, currency swings between the euro and dollar affect reported results and the dollar value of the dividend, adding volatility unrelated to the business. Pharma also faces pricing pressure, US drug-pricing policy, patent litigation, and competition from large rivals and biosimilars. Vaccine demand is seasonal and competitive, as Beyfortus experienced in the US market. The share price has reflected these worries: SNY touched a 52-week low of ~$39 in October 2026 and RBC cut its Paris-share target to 75 euros from 80. The third-quarter beat brought a ~12% rebound in the month to November 20, but the ADR is still down about 3% for the year at ~$46.58. Deal risk is new: Bloomberg reported in November 2026 that Sanofi is weighing a takeover of Insmed that could be the largest biotech deal since Pfizer's $43 billion Seagen purchase, and a deal of that size would bring integration risk and could absorb cash otherwise returned to shareholders. Reported net income has been volatile, including a loss in the December 2025 quarter.
Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell ARQT or SNY; figures are approximate and dated (as of November 2026). Verify current data before investing.